Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
BioPharma Dive3h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
FDA approves drug from Boston-based company to treat pain without opioid effects
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
WHDH7h
FDA approves first new type of pain medication in 25 years
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
WBUR8h
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...
Ironwood Pharma: Strategic Growth Amidst Challenges, Driven by Apra’s Potential
Mohit Bansal, an analyst from Wells Fargo, assigned the Buy rating on Ironwood Pharma (IRWD – Research Report). The associated price target is ...
PipelineReview.com12h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- ...